Delving into the Latest Updates on Squaric acid dibutyl ester(Squarex) with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Quadratic-acid-dibutylester, SADBE, Squaric acid dibutyl ester

+ [4]

Target-

Action

modulators

Mechanism

Immunomodulators

Therapeutic Areas

Infectious DiseasesMouth and Tooth DiseasesSkin and Musculoskeletal Diseases

Active Indication-

Inactive Indication

Herpes Labialis

Originator Organization

Squarex

Active Organization-

Inactive Organization

Squarex

License Organization-

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC12H18O4

InChIKeyXBRWELTXMQSEIN-UHFFFAOYSA-N

CAS Registry2892-62-8

The purpose of this study is to answer: how do inflammation and anti-inflammatory skin therapies work in the skin? Inflammation is a protective response from the body's immune system to injury, disease, or irritation. It is a process by which your body's white blood cells and the things they make protect you from infection from outside invaders such as bacteria and viruses.

Start Date15 Nov 2022

Sponsor / Collaborator

Massachusetts Institute of Technology

NCT05414266

/ Unknown statusEarly Phase 1IIT

A Randomized, Placebo Controlled Single Site Study Evaluating Efficacy of Topical Squaric Acid Dibutyl Ester in Children and Adolescents With Alopecia Areata

The purpose of this study is to evaluate the efficacy and tolerability of squaric acid dibutylester (SADBE) in children and adolescents with alopecia areata (AA) and to evaluate effect of squaric acid dibutyl ester on patient-centered outcomes and payer relevant measures to assess treatment benefit from the patient perspective and to demonstrate value

Start Date15 Aug 2022

Sponsor / Collaborator

University of Texas Health Science Center at Houston

NCT04999631

/ Not yet recruitingEarly Phase 1IIT

Neoadjuvant Squaric Acid Dibutylester Treatment of Melanocytes in Congenital Melanocytic Nevi

A study to evaluate the safety and efficacy topical squaric acid dibutylester (SADBE) for the neoadjuvant treatment of congenital melanocytic nevi (CMN).

Start Date01 Jan 2022

Sponsor / Collaborator

The General Hospital Corp.

100 Clinical Results associated with Squaric acid dibutyl ester(Squarex)

Login to view more data

100 Translational Medicine associated with Squaric acid dibutyl ester(Squarex)

Login to view more data

100 Patents (Medical) associated with Squaric acid dibutyl ester(Squarex)

Login to view more data

303

Literatures (Medical) associated with Squaric acid dibutyl ester(Squarex)

01 May 2025·Journal of Investigative Dermatology

Single-Cell RNA Sequencing Reveals Molecular Signatures that Distinguish Allergic from Irritant Contact Dermatitis

Article

Author: Wang, Yuqing ; Martinez, Nuria ; Harris, John E. ; Harris, John E ; Ko, Wei-Che C. ; Frisoli, Michael L ; Frisoli, Michael L. ; Garber, Manuel ; Afshari, Khashayar ; Ko, Wei-Che C

Allergic contact dermatitis (ACD) is a pruritic skin disease caused by environmental chemicals that induce cell-mediated skin inflammation within susceptible individuals. Irritant contact dermatitis (ICD) is caused by direct damage to the skin barrier by environmental insults. Diagnosis can be challenging because both types of contact dermatitis can appear similar by visual examination, and histopathological analysis does not reliably distinguish ACD from ICD. To discover specific biomarkers of ACD and ICD, we characterized the transcriptomic and proteomic changes that occur within the skin during each type of contact dermatitis. We induced ACD and ICD in healthy human volunteers and sampled skin using a nonscarring suction blister biopsy method that collects interstitial fluid and cellular infiltrate. Single-cell RNA sequencing analysis revealed that cell-specific transcriptome differences rather than cell-type proportions best distinguished ACD from ICD. Allergy-specific genes were associated with upregulation of IFNG, and cell signaling network analysis implicated several other genes such as IL4, despite their low expression levels. We validated transcriptomic differences with proteomic assays on blister fluid and trained a logistic regression model on skin interstitial fluid proteins that could distinguish ACD from ICD and healthy control skin with 93% sensitivity and 93% specificity.

03 Mar 2025·ChemBioChem

Hydrophobic Domain Modulation of Chemical Responsiveness in a Bolaamphiphile‐Based Supramolecular Monomer

Article

Author: Fehér, Bence ; van Zwol, Suzanne ; Voets, Ilja K. ; Vittala, Sandeepa K. ; Kieltyka, Roxanne E. ; Liu, Tingxian

AbstractSelf‐immolative chemistries that respond in an irreversible manner to external stimuli are highly attractive to permanently degrade filamentous supramolecular biomaterials. Within the monomer, a balance needs to be struck between its capacity to be supramolecularly polymerized and degraded at an appropriate rate for a given application. Herein, we unravel the structure‐property‐function relationships of a library of squaramide‐based bolaamphiphiles bearing a central disulfide‐based self‐immolative spacer to construct supramolecular polymers responsive to chemical stimuli in aqueous solutions. We examine the impact of changing the alkyl domain length (2 to 12 methylene units) on the formation of supramolecular filaments and their rate of degradation in response to a biological antioxidant, glutathione. A minimum of an octyl spacer is required to robustly form supramolecular polymers that can be irreversibly degraded through a cyclization‐elimination reaction of the self‐immolative spacer triggered by thiol‐disulfide exchange. Further increasing the peripheral alkyl chain length to a decyl spacer increases the ordered packing of the amphiphiles, hindering their chemical degradation. This study provides a framework to design chemically responsive filamentous supramolecular polymers based on bolaamphiphiles that can be irreversibly degraded in aqueous solutions for their eventual application as biomedical materials.

31 Dec 2024·Journal of Dermatological Treatment

Alopecia areata treatment with baricitinib: different relapse phenotypes

Article

Author: Vitale, Pasquale ; Lacarrubba, Francesco ; Dall’Oglio, Federica ; Nasca, Maria Rita ; Micali, Giuseppe

A 28-yr-old woman with a history of AA universalis since 5 years of age with transient response to different AA treatments, including intralesional corticosteroids, contact immunotherapy with squaric acid dibutylester (SAdBe), cyclosporine, and methotrexate.Laboratory investigations were unremarkable, showing only mild anemia.Trichoscopy, showing black dots and exclamation mark hairs, and histopathol. confirmed the diagnosis of active AA.A 43-yr-old woman with severe AA (SALt = 70) occurred 2 years earlier.A 52-yr-old woman with severe AA (SALt = 90) occurred 2 years earlier unresponsive to previous treatments with systemic corticosteroids and methotrexate.Our observations confirm that AA relapses may occur during baricitinib treatment.Interestingly, hair loss developed either within the regrowth area as seen in Cases 1 and 3 or in a healthy area previously unaffected as in Case 2, confirming two different presentation phenotypes.

100 Deals associated with Squaric acid dibutyl ester(Squarex)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB12223

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Herpes Labialis	Phase 2	United States	Squarex	12 Mar 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02965781 (P2a, CTgov)	Phase 1/2	Herpes Labialis	139	Placebo (Placebo Application (DMSO Only-No SADBE))	toxskkycrk(amviqlizrr) = pssxgriinv zyyqdorjiz (qaqxphjdwz, vpvurqbdqj - fbwbazkpua) View more	-	02 Nov 2021
				SADBE (Two SADBE Applications)	toxskkycrk(amviqlizrr) = perlpzpkuy zyyqdorjiz (qaqxphjdwz, fodsijjkjn - aivevtvayi) View more
NCT03521479 (CTgov)	Phase 2	Herpes Labialis	40	Squaric Acid Dibutyl Ester (Group A)	fbmbnzdpug(ypzmuyljxn) = twgayywlov qrfzqeqfcp (wgkrpjyktc, kyxytwzyiy - jwaeejjntg) View more	-	15 Jun 2021
				Squaric Acid Dibutyl Ester (Group B)	fbmbnzdpug(ypzmuyljxn) = qjmhgfzvfq qrfzqeqfcp (wgkrpjyktc, umbxijfgpu - obyfludhvb) View more
NCT01971385 (Squarex, CTgov)	Phase 1	Herpes Labialis	54	Squaric Acid solution (2% Squaric Acid Sensitization)	hcojxwskmg(emnttofvrz) = pcpaxnmyxo qxnrbwrgld (nulovfvsrn, xkidkdqrfy - kidiigbytx)	-	02 Oct 2017
				Placebo solution (Placebo Solution)	hcojxwskmg(emnttofvrz) = mplylwritg qxnrbwrgld (nulovfvsrn, dcmnlrvkiu - lafimrsteo) View more